{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"INTerpath-009","nct_id":"NCT06623422","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=interpath-009-nct06623422. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"For neoadjuvant treatment, participants will receive pembrolizumab 200 mg via intravenous (IV) infusion every 3-week cycle for up to 4 cycles PLUS background chemotherapy via IV infusion (cisplatin 75 mg/m\\^2 or carboplatin area under the curve \\[AUC\\] 5 or 6 mg/mL/min, pemetrexed 500 mg/m\\^2, gemcitabine 1000 mg/m\\^2, paclitaxel 175 mg/m\\^2 or 200 mg/m\\^2 given at a dose and combination per investigator's choice) every 3-week cycle for up to 4 cycles (total neoadjuvant treatment duration of up to \\~12 weeks). After surgical resection, for adjuvant treatment, participants will receive pembrolizumab 400 mg via IV infusion every 6-week cycle for up to 7 cycles PLUS intismeran autogene 1 mg via intramuscular (IM) injection every 3 weeks for up to 9 doses (total adjuvant treatment duration of up to \\~42 weeks).","label":"Pembrolizumab + Intismeran autogene","type":"EXPERIMENTAL"},{"description":"For neoadjuvant treatment, participants will receive pembrolizumab 200 mg via IV infusion every 3-week cycle for up to 4 cycles PLUS background chemotherapy via IV infusion (cisplatin 75 mg/m\\^2 or carboplatin AUC 5 or 6 mg/mL/min, pemetrexed 500 mg/m\\^2, gemcitabine 1000 mg/m\\^2, paclitaxel 175 mg/m\\^2 or 200 mg/m\\^2 given at a dose and combination per investigator's choice) every 3-week cycle for up to 4 cycles (total neoadjuvant treatment duration of up to \\~12 weeks). After surgical resection, for adjuvant treatment, participants will receive pembrolizumab 400 mg via IV infusion every 6-week cycle for up to 7 cycles PLUS matching placebo via IM injection every 3 weeks for up to 9 doses (total adjuvant treatment duration of up to \\~42 weeks).","label":"Pembrolizumab + Placebo","type":"ACTIVE_COMPARATOR"}],"collaborators":["ModernaTX, Inc."],"completion_date":{"date":"2038-01-26","type":"ESTIMATED"},"conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":{"count":680,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Pembrolizumab","otherNames":["MK-3475","KEYTRUDA®"],"type":"BIOLOGICAL"},{"name":"Cisplatin","otherNames":["Platinol®","Platinol®-AQ"],"type":"DRUG"},{"name":"Carboplatin","otherNames":["Paraplatin®"],"type":"DRUG"},{"name":"Pemetrexed","otherNames":["Alimta®"],"type":"DRUG"},{"name":"Gemcitabine","otherNames":["Gemzar"],"type":"DRUG"},{"name":"Paclitaxel","otherNames":["Taxol®","Onxol®"],"type":"DRUG"},{"name":"Intismeran autogene","otherNames":["mRNA-4157","V940"],"type":"BIOLOGICAL"},{"name":"Placebo","otherNames":[],"type":"OTHER"}],"last_update":"2026-10-16","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2033-05-16","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Disease-Free Survival (DFS)","timeFrame":"Up to ~97 months"}],"references":[],"start_date":{"date":"2024-10-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)","url":"https://clinicaltrials.gov/study/NCT06623422"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/interpath-009-nct06623422"}